Following incorporation into muscle cells, oxygen is needed to transport oxidation products out of the cells in exchange for CO2, so an anaerobic metabolism is not feasible. The integration of CO2-exchange processes into the muscle cell, using an external artificial organ that exchanges CO2 for the acetylcoenzyme A (acetyl-CoA) through the Monod-Jakobsson reaction, followed by a second round of acetyl-CoA synthesis to produce the myoglobin in the artificial organ would create an artificial muscle using the basic structure of a red muscle cell. This artificial muscle would use oxygen as the electron acceptor and deliver free iron and sulfur concentrations to the cell.121 If a sufficient concentration of ATP is made available to the cell, anaerobic protein synthesis with lactate as the end product can be sustained.122 In vitro meat is expected to be a product of the future, and thorough research has not been conducted into the side effects of other molecules and processes during the formation of the tissue product. The animal fat obtained from the in vitro meat production process can be either used as a food or used as a raw material for the production of chemicals such as hydrogen and lipids. In the former case, the medium-chain fatty acids can be extracted and used as a food or food additive.123 The opposite process that creates a lipid-rich raw material for the chemical production process is the lipid extraction from the animal muscle tissue.
One of the major problems in organ protection is that the drugs can have pharmacokinetic and/or pharmacodynamic interactions with each other. Therefore, any combination of drugs that has the chance to be administered during dialysis should be avoided. If required, the drugs should be administered before the dialysis, if the drugs can be administered before the dialysis. There are several scenarios that may occur during dialysis from kidney failure, and pre-dialysis glycemic control is highly recommended in diabetic patients receiving chronic hemodialysis. Therefore, patient selection for continuous glucose infusion (CGI) during hemodialysis is based on glycemic control from moderate to severe hyperglycemia and the ability to withstand the procedure. Individualized treatment of dialysis by the endocrinologist and nephropathologist is required to achieve optimal management. d2c66b5586